CY1123181T1 - Υποκινητης pr13.5 για ισχυρες αποκρισεις τ-κυτταρων και αντισωματων - Google Patents
Υποκινητης pr13.5 για ισχυρες αποκρισεις τ-κυτταρων και αντισωματωνInfo
- Publication number
- CY1123181T1 CY1123181T1 CY20201100630T CY201100630T CY1123181T1 CY 1123181 T1 CY1123181 T1 CY 1123181T1 CY 20201100630 T CY20201100630 T CY 20201100630T CY 201100630 T CY201100630 T CY 201100630T CY 1123181 T1 CY1123181 T1 CY 1123181T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cell
- antibody responses
- strong
- hypomotor
- mva
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η εφεύρεση περιλαμβάνει ανασυνδυασμένους ιούς της ευλογιάς, κατά προτίμηση τροποποιημένους ιούς δαμαλίτιδας τύπου Ankara (MVA), που περιλαμβάνουν έναν υποκινητή Pr 13.5 λειτουργικά συνδεδεμένο με μια αλληλουχία νουκλεοτιδίων που κωδικοποιεί ένα αντιγόνο και χρήσεις αυτών. Η εφεύρεση βασίζεται σε συνθέσεις και μεθόδους για την επαγωγή ισχυρών αποκρίσεων CD8 Τ κυττάρων και αντισωμάτων σε ένα συγκεκριμένο(-α) αντιγόνο(-α) με χορήγηση μίας ή περισσοτέρων ανοσοποιήσεων του ανασυνδυασμένου MVA σε ένα θηλαστικό, κατά προτίμηση σε έναν άνθρωπο.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719429P | 2012-10-28 | 2012-10-28 | |
| PCT/EP2013/003239 WO2014063832A1 (en) | 2012-10-28 | 2013-10-28 | Pr13.5 promoter for robust t-cell and antibody responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123181T1 true CY1123181T1 (el) | 2021-10-29 |
Family
ID=49513897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100630T CY1123181T1 (el) | 2012-10-28 | 2020-07-08 | Υποκινητης pr13.5 για ισχυρες αποκρισεις τ-κυτταρων και αντισωματων |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9828414B2 (el) |
| EP (2) | EP3778904A1 (el) |
| JP (2) | JP6505016B2 (el) |
| KR (2) | KR20200087880A (el) |
| CN (1) | CN104755622B (el) |
| AU (1) | AU2013337018B2 (el) |
| BR (1) | BR112015009320A2 (el) |
| CA (1) | CA2887623C (el) |
| CY (1) | CY1123181T1 (el) |
| DK (1) | DK2912183T3 (el) |
| EA (2) | EA032498B1 (el) |
| ES (1) | ES2800623T3 (el) |
| HK (1) | HK1212383A1 (el) |
| HU (1) | HUE049706T2 (el) |
| IL (1) | IL238130B (el) |
| IN (1) | IN2015DN03326A (el) |
| LT (1) | LT2912183T (el) |
| MX (2) | MX2015005264A (el) |
| MY (2) | MY171687A (el) |
| NZ (1) | NZ706637A (el) |
| PT (1) | PT2912183T (el) |
| SG (2) | SG10201704657WA (el) |
| SI (1) | SI2912183T1 (el) |
| UA (1) | UA118340C2 (el) |
| WO (1) | WO2014063832A1 (el) |
| ZA (1) | ZA201502892B (el) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2912183T (pt) * | 2012-10-28 | 2020-06-05 | Bavarian Nordic As | Promotor pr13.5 para respostas robustas de células t e anticorpos |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| EP3407910B1 (en) | 2016-01-29 | 2022-04-13 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
| JP7053491B2 (ja) * | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
| RU2756534C2 (ru) | 2016-09-28 | 2021-10-01 | Бавариан Нордик А/С | Композиции и способы для повышения стабильности трансгенов в поксвирусах |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| BR112019026126A2 (pt) * | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| MX2020001856A (es) | 2017-08-24 | 2020-07-13 | Bavarian Nordic As | Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. |
| CA3086325A1 (en) | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
| GB201807932D0 (en) * | 2018-05-16 | 2018-06-27 | Redchenko Irina | Compositions and methods for inducing an immune response |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CN110904127A (zh) | 2018-09-18 | 2020-03-24 | 瓦赫宁恩研究基金会 | 非洲猪瘟病毒疫苗 |
| AU2019354101A1 (en) | 2018-10-05 | 2021-04-15 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| EP3883599A1 (en) | 2018-11-20 | 2021-09-29 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| IL293009A (en) | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Recombinant mva viruses for intratumoral and/or intravenous administration for cancer treatment |
| KR20230022206A (ko) | 2020-06-10 | 2023-02-14 | 버베리안 노딕 에이/에스 | 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신 |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| KR20240051214A (ko) | 2021-09-03 | 2024-04-19 | 버베리안 노딕 에이/에스 | 변형 백시니아 바이러스 앙카라(mva)에 의한 세포독성 전이유전자 발현의 하향조절을 위한 마이크로rna의 활용 |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
| WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| AU2002231639B2 (en) | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| EP1773387B1 (en) * | 2004-06-25 | 2013-06-12 | Merial Ltd. | Avipox recombinants expressing foot and mouth disease virus genes |
| JP2008301792A (ja) | 2007-06-11 | 2008-12-18 | National Univ Corp Shizuoka Univ | 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法 |
| US8772023B2 (en) | 2008-11-27 | 2014-07-08 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| PT2912183T (pt) * | 2012-10-28 | 2020-06-05 | Bavarian Nordic As | Promotor pr13.5 para respostas robustas de células t e anticorpos |
-
2013
- 2013-10-28 PT PT137838520T patent/PT2912183T/pt unknown
- 2013-10-28 AU AU2013337018A patent/AU2013337018B2/en active Active
- 2013-10-28 DK DK13783852.0T patent/DK2912183T3/da active
- 2013-10-28 MY MYPI2015701223A patent/MY171687A/en unknown
- 2013-10-28 MY MYPI2018001787A patent/MY194609A/en unknown
- 2013-10-28 NZ NZ706637A patent/NZ706637A/en unknown
- 2013-10-28 LT LTEP13783852.0T patent/LT2912183T/lt unknown
- 2013-10-28 WO PCT/EP2013/003239 patent/WO2014063832A1/en active Application Filing
- 2013-10-28 CA CA2887623A patent/CA2887623C/en active Active
- 2013-10-28 BR BR112015009320A patent/BR112015009320A2/pt not_active Application Discontinuation
- 2013-10-28 ES ES13783852T patent/ES2800623T3/es active Active
- 2013-10-28 EA EA201590831A patent/EA032498B1/ru not_active IP Right Cessation
- 2013-10-28 UA UAA201505223A patent/UA118340C2/uk unknown
- 2013-10-28 JP JP2015538330A patent/JP6505016B2/ja active Active
- 2013-10-28 SI SI201331731T patent/SI2912183T1/sl unknown
- 2013-10-28 EA EA201990114A patent/EA201990114A1/ru unknown
- 2013-10-28 EP EP20172647.8A patent/EP3778904A1/en active Pending
- 2013-10-28 EP EP13783852.0A patent/EP2912183B1/en active Active
- 2013-10-28 SG SG10201704657WA patent/SG10201704657WA/en unknown
- 2013-10-28 IN IN3326DEN2015 patent/IN2015DN03326A/en unknown
- 2013-10-28 US US14/437,939 patent/US9828414B2/en active Active
- 2013-10-28 KR KR1020207020263A patent/KR20200087880A/ko not_active Application Discontinuation
- 2013-10-28 SG SG11201503200PA patent/SG11201503200PA/en unknown
- 2013-10-28 CN CN201380054013.0A patent/CN104755622B/zh active Active
- 2013-10-28 KR KR1020157009206A patent/KR102135818B1/ko active IP Right Grant
- 2013-10-28 HU HUE13783852A patent/HUE049706T2/hu unknown
- 2013-10-28 MX MX2015005264A patent/MX2015005264A/es unknown
-
2015
- 2015-04-02 IL IL238130A patent/IL238130B/en active IP Right Grant
- 2015-04-24 MX MX2021001638A patent/MX2021001638A/es unknown
- 2015-04-28 ZA ZA2015/02892A patent/ZA201502892B/en unknown
-
2016
- 2016-01-12 HK HK16100267.8A patent/HK1212383A1/xx unknown
-
2017
- 2017-11-22 US US15/821,035 patent/US11028130B2/en active Active
-
2019
- 2019-03-22 JP JP2019054129A patent/JP6818797B2/ja active Active
-
2020
- 2020-07-08 CY CY20201100630T patent/CY1123181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123181T1 (el) | Υποκινητης pr13.5 για ισχυρες αποκρισεις τ-κυτταρων και αντισωματων | |
| CY1122720T1 (el) | Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1122833T1 (el) | Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7 | |
| CY1123005T1 (el) | Κατασκευασματα αντισωματος για cdh19 και cd3 | |
| CY1122754T1 (el) | Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r | |
| CY1124095T1 (el) | Μεθοδοι για την ενισχυση της ειδικης ανοσοθεραπειας εναντι αλλεργιογονου με χορηγηση αναστολεα του ιl-4r | |
| CY1123435T1 (el) | Anti-pd-l1 αντισωματα και χρησεις αυτων | |
| CY1124867T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1126145T1 (el) | Κατασκευασματα αντισωματων για flt3 και cd3 | |
| CY1124558T1 (el) | Προβλεψη επιτοπων τ κυτταρων χρησιμων για εμβολιασμο | |
| CO2019006914A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
| CY1124437T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
| NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
| CY1118943T1 (el) | Anti-pd-l1 αντισωματα και χρηση αυτων για την ενισχυση της λειτουργιας τ-κυτταρων | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1121993T1 (el) | Συνθεσεις που χαρακτηριζονται απο εναν εξασθενημενο ιο ψευδοπανωλης και μεθοδοι χρησης για την αντιμετωπιση της νέοπλασιας | |
| CY1120177T1 (el) | Φλαγκελλινη roseburia και ανοσορυθμιση | |
| CY1120740T1 (el) | Βελτιωμενα ευλογοϊικα εμβολια | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| CY1117650T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r |